A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (Hoffmann-LaRoche GO42784)
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician’s choice (TPC: eltrozole, anastrozole, exemestane, or tamoxifen) in participants with medium- and highrisk Stage I-III histologically confirmed ER+ and HER2- EBC. Participants will be treated with giredestrant or TPC for at least 5 years. During the study, participants will be regularly assessed for efficacy, safety, and HRQoL. After completing the study treatment phase, participants will enter long-term follow-up for at least 5 years.
Steve Lo, MD
ContactMary Miller, LPN at 203-358-8879 or [email protected]
Bennett Cancer Center
Stamford, CT 06902